BC Innovations | Jul 10, 2018
Distillery Therapeutics


INDICATION: Small cell lung cancer Patient sample and cell culture studies suggest promoting IGFBP5 expression or inhibiting POU2F3 or IGF1R could help treat POU2F3-expressing small cell lung cancer (SCLC). In tumor samples from SCLC patients,...
BC Extra | Jun 27, 2018
Preclinical News

New small cell lung cancer subtype identified

In a Genes & Development paper , scientists at Cold Spring Harbor Laboratory identified a new subtype of small cell lung cancer defined by high levels of POU class 2 homeobox 3 (POU2F3; OCT11) and suggest...
BC Week In Review | Jun 2, 2008
Company News

OncoGenex Technologies, Sonus deal

OncoGenex and Sonus will merge to form OncoGenex Pharmaceuticals Inc. Sonus and OncoGenex shareholders each will own 50% of the combined company. OncoGenex shareholders will receive about 37 million shares of Sonus, valued at $12.2...
BC Week In Review | Sep 15, 2003
Company News

Isis, OncoGenex Technologies deal

The companies expanded their 2001 deal to co-develop and market OGX-011 to treat prostate cancer. The antisense compound inhibits clusterin . As expanded, the partnership will include second-generation drug candidate OGX-225 , which is in preclinical development....
Items per page:
1 - 4 of 4